000 05700nam a22005415i 4500
001 978-3-319-90603-4
003 DE-He213
005 20210201191408.0
007 cr nn 008mamaa
008 180620s2018 gw | s |||| 0|eng d
020 _a9783319906034
_9978-3-319-90603-4
050 4 _aRS380
050 4 _aRS190-210
072 7 _aTDCW
_2bicssc
072 7 _aMED072000
_2bisacsh
072 7 _aTDC
_2thema
082 0 4 _a615.19
_223
245 1 0 _aChallenges in Protein Product Development
_h[electronic resource] /
_cedited by Nicholas W. Warne, Hanns-Christian Mahler.
250 _a1st ed. 2018.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2018.
300 _aXVI, 599 p. 130 illus., 75 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aAAPS Advances in the Pharmaceutical Sciences Series,
_x2210-7371 ;
_v38
500 _aAcceso multiusuario
505 0 _aPart 1. Formulation Development of Biologics -- Introduction into Formulation Development of Biologics -- Part 2. Challenges with Excipients -- Polysorbate Degradation and Quality -- Sucrose and Trehalose in Therapeutic Protein Formulations -- Part 3. High Concentration Proteins -- Introduction to High-Concentration Proteins -- Solubility, Opalescence & Particulate Matter -- Analytical Characterization and Predictive Tools for Highly Concentrated Protein Formulations -- Practical Considerations for High Concentration Protein Formulations -- Part 4. Container-Closure Systems -- Parenteral Container Closure Systems -- Development of Prefilled Syringe Combination Products for Biologics -- Special Topics in Analytics of Pre-filled Syringes -- C Mini-Pumps -- Container Closure Integrity Testing of Primary Containers for Parenteral Products -- Chemical Durability of Glass - Delamination -- Part 5. Processing Considerations -- Bulk Protein Solution: Freeze Thaw Process, Storage and Shipping Considerations -- Leachables and Extractables: From Regulatory Expectations to Laboratory Assessment -- Biotherapeutic Drug Product Manufacturing and Process Development -- Line Sterilization Considerations and VHP -- Lyophilization: Process Design, Robustness and Risk Management -- Fogging -- Scientific Approaches for the Application of QbD Principles in Lyophilization Process Development -- Manufacturing of Highly Potent Drug Product in a Clinical Multi-Product Aseptic Facility and Transfer of Principles to Antibiotic Drug Product -- Part 6. Novel Constructs -- Introduction into Novel Constructs -- Novel Constructs - Half-Life Extensions -- Fc Fusion Proteins -- Part 7. Lifecycle Management -- Lifecycle Management of Biotherapeutic Dosage Forms -- Switching from an IV to an SC Formulation - Considerations for Formulation Development and Formulation Bridging.
520 _aIn this volume, the authors discuss the many significant challenges currently faced in biotechnology dosage form development, providing guidance, shared experience and thoughtful reflection on how best to address these potential concerns. As the field of therapeutic recombinant therapeutic proteins enters its fourth decade and the market for biopharmaceuticals becomes increasingly competitive, companies are increasingly dedicating resources to develop innovative biopharmaceuticals to address unmet medical needs. Often, the pharmaceutical development scientist is encountering challenging pharmaceutical properties of a given protein or by the demands placed on the product by stability, manufacturing and preclinical or clinical expectations, as well as the evolving regulatory expectations and landscape. Further, there have been new findings that require close assessment, as for example those related to excipient quality, processing, viscosity and device compatibility and administration, solubility and opalescence and container-closure selection. The literature varies widely in its discussion of these critical elements and consensus does not exist. This topic is receiving a great deal of attention within the biotechnology industry as well as with academic researchers and regulatory agencies globally. Therefore, this book is of interest for business leaders, researchers, formulation and process development scientists, analytical scientists, QA and QC officers, regulatory staff, manufacturing leaders and regulators active in the pharmaceutical and biotech industry, and expert reviewers in regulatory agencies.
541 _fUABC ;
_cTemporal ;
_d01/01/2021-12/31/2023.
650 0 _aPharmaceutical technology.
650 1 4 _aPharmaceutical Sciences/Technology.
_0https://scigraph.springernature.com/ontologies/product-market-codes/B21010
700 1 _aWarne, Nicholas W.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aMahler, Hanns-Christian.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783319906010
776 0 8 _iPrinted edition:
_z9783319906027
776 0 8 _iPrinted edition:
_z9783030080525
830 0 _aAAPS Advances in the Pharmaceutical Sciences Series,
_x2210-7371 ;
_v38
856 4 0 _zLibro electrónico
_uhttp://148.231.10.114:2048/login?url=https://doi.org/10.1007/978-3-319-90603-4
912 _aZDB-2-SBL
912 _aZDB-2-SXB
942 _cLIBRO_ELEC
999 _c242992
_d242991